Skip to main content

Advertisement

SpringerLink
Log in

The Utility of the “NAFLD Fibrosis Score” in Morbidly Obese Subjects with NAFLD

  • Research Article
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

To date, the noninvasive diagnostic tests for hepatic fibrosis in subjects with nonalcoholic fatty liver disease (NAFLD) have proven to be suboptimal. We evaluated the validity of a recently proposed “NAFLD fibrosis score” to identify liver fibrosis in morbidly obese individuals with elevated and normal alanine aminotransferase (ALT) levels.

Methods

Medical records of 401 patients that underwent a gastric bypass operation and intraoperative liver biopsy were analyzed. Three hundred thirty one patients with biopsy-proven NAFLD were included in the study (group A). These patients were divided into two ALT groups based on their levels according to the new proposed normal range: group B elevated level (ALT > 19 U/L in females and >30 U/L in males, n = 221) and group C normal ALT (n = 110). Diagnostic accuracy of the system was assessed for the presence/absence of any fibrosis, significant fibrosis (stage 2–4), and advanced fibrosis (stages 3 and 4) in all of the groups.

Results

The prevalence of advanced fibrosis in our cohort was about 14%. The low NAFLD fibrosis score demonstrated high accuracy for ruling out advanced fibrosis, with negative predictive value (NPV) of 98 and 99% in groups A and B, respectively. The NPV for significant fibrosis in groups A, B, and C was 87, 88, and 88%, respectively. The respective positive predictive value for the high NAFLD fibrosis score for the presence of any fibrosis was 88, 95, and 77% in groups A, B, and C.

Conclusions

The NAFLD fibrosis score may be a useful noninvasive approach for excluding significant and advanced fibrosis and in morbidly obese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44–52.

    Article  PubMed  Google Scholar 

  2. Gholam P, Kotler D, Flancbaum L. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2002;12:49–51.

    Article  PubMed  Google Scholar 

  3. Ong J, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines H, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310–5.

    Article  PubMed  Google Scholar 

  4. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.

    Article  PubMed  CAS  Google Scholar 

  5. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898–906.

    Article  PubMed  Google Scholar 

  6. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6.

    Article  PubMed  Google Scholar 

  7. Angulo P, Hui J, Marchesini G, Bugianesi E, George J, Farrell G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846–54.

    Article  PubMed  CAS  Google Scholar 

  8. Mofrad P, Contos M, Haque M, Sargeant C, Fisher R, Luketic V, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286–92.

    Article  PubMed  Google Scholar 

  9. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.

    PubMed  CAS  Google Scholar 

  10. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005;42:650–6.

    Article  PubMed  Google Scholar 

  11. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.

    Article  PubMed  Google Scholar 

  12. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117–23.

    Article  PubMed  CAS  Google Scholar 

  13. Abrams G, Kunde S, Lazenby A, Clements R. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004;40:475–83.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Alabama, Birmingham, AL, USA

    Kamran Qureshi

  2. Department of Surgery, University of Alabama, Birmingham, AL, USA

    Ronald H. Clements

  3. Department of Medicine, UAB Health Center Montgomery, University of Alabama, 2055 East South Blvd (Morrow Tower), Suite 806, Montgomery, AL, 36116, USA

    Gary A. Abrams

Authors
  1. Kamran Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald H. Clements
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary A. Abrams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary A. Abrams.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qureshi, K., Clements, R.H. & Abrams, G.A. The Utility of the “NAFLD Fibrosis Score” in Morbidly Obese Subjects with NAFLD. OBES SURG 18, 264–270 (2008). https://doi.org/10.1007/s11695-007-9295-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-007-9295-8

Keywords

Search

Navigation